Quicker Action Needed on HIV Prevention
An AIDS advocacy group says donors and researchers need to work smarter and faster to introduce prevention methods that people will actually use. AVAC says not enough has been done to capitalize on lessons learned from recent studies. AVAC Executive Director Mitchell Warren said that it’s time for a “reality check” in HIV prevention research.
December 9, 2013 — Voice of America
New Achievements on AIDS Show Targets Matter — So Let’s Set New Ones
As a result of work funded through the President’s Emergency Plan for AIDS Relief (PEPFAR), an estimated 1 million children have been born free of HIV and 6.7 million people now receive lifesaving anti-retroviral treatment.
December 6, 2013 — Huffington Post
Analysis: How to prepare for an HIV/AIDS vaccine?
Increased attention to the delivery of HIV prevention and treatment programmes is needed to prepare communities for a potential roll-out of a vaccine, which will most probably be partially-effective, experts say. “How to deliver a 31 percent effective vaccine – it’s hard stuff, it’s uncharted territory, and it’s un-costed territory,” Mitchell Warren, executive director of the New York-based NGO AIDS Vaccine Advocacy Coalition (AVAC), told IRIN.
October 23, 2013 — IRIN
Charting succes in battling AIDS
About a dozen countries hit hard by AIDS have reached a “tipping point” that means they are winning their battles against the disease, according to a new analysis.
October 7, 2013 — New York Times
Why is no one on the first treatment to prevent HIV?
In November, 2010, the New England Journal of Medicine published the results of a three-year clinical trial, funded by the National Institutes of Health, announcing the arrival of a treatment that could reduce the risk of contracting H.I.V. by more than ninety per cent. But, in fact, adoption of the drug has been slow. According to Dawn Smith, a biomedical interventions implementation officer in the C.D.C.’s epidemiology branch, at least half a million Americans are good candidates for PrEP—meaning that they are at high risk for contracting H.I.V.
October 1, 2013 — The New Yorker
AVAC evaluates range of vaccine trials across the world
Although we have yet to discover a vaccine to prevent HIV infection or lower viral load, there are currently 30 candidates moving forward in clinical trials across the world. AVAC: Global Advocacy for HIV Prevention’s Executive Director Mitchell Warren spoke to EDGE about current human clinical trials in Thailand and South Africa that show promise.
September 27, 2013 — Edge on the Net
HIV rates reach historic low in children
About 260,000 children were affected by the AIDS-causing virus in 2012, a 52% drop since 2001, the UNAIDS report found. In addition, the combined rate in children and adults fell to 2.3 million new infections, a 33% reduction during the same time period.
September 23, 2013 — MSNBC
Uganda rejects HIV prevention tool on moral grounds
Activists in Uganda, where some 400 people are infected with HIV every day, have called on the government to rethink its dismissal of an emerging prevention protocol demonstrated to be effective in a trial conducted partly in Uganda, and which has been approved by the US Food and Drug Administration.
September 3, 2013 — IRIN
Experts urge renewed push on US-Thai HIV vaccine
Health experts on Thursday called for trials of an HIV vaccine under development in Thailand to be speeded up following recent setbacks in other efforts to end the AIDS epidemic.
August 29, 2013 — Agence France Press
HIV prevention R&D funding in 2012: Is the end of the epidemic at risk?
Our recent report,From Research to Reality: Investing in HIV Prevention Research in a Challenging Landscape, shows that US $1.3 billion in 2012 enabled sustained investment in new and potentially powerful preventive tools like vaccines and microbicides, and emerging prevention methods such as voluntary adult male circumcision, pre-exposure prophylaxis (PrEP), prevention of mother to child HIV transmission (PMTCT), and treatment-as-prevention.
July 23, 2013 — The Lancet Global Health Blog
Investment into HIV prevention research could speed up breakthroughs
A broader base of funders is needed to sustain support for HIV prevention research, which continues to make breakthroughs that could help to end the AIDS epidemic, according to a report released on Saturday.
July 5, 2013 — Vaccine News Daily
Walk the talk: New WHO guidelines on HIV treatment and prevention
The new World Health Organization (WHO) guidelines on HIV treatment and prevention which were released at the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur do provide hope that more people living with HIV will be able to live healthy – only if these guidelines get implemented in letter and spirit on the ground.
July 3, 2013 — Asian Tribune
Death of AIDS in sight
A trial of the only vaccine to offer partial protection from HIV, after 30 years of research, was started in South Africa this week.
June 21, 2013 — Times (South Africa)
Once-a-day pill prevents HIV in drug users
A once-a-day pill can protect people who inject drugs such as heroin from the AIDS virus, lowering their risk by nearly 50 percent, researchers reported Wednesday.
June 12, 2013 — NBC News
U.S.-backed HIV vaccine fails; study halted
The National Institutes of Health on Thursday halted a study testing an experimental HIV vaccine after an independent review board found the vaccine did not prevent HIV infection and did not reduce the amount of HIV in the blood. “This trial has provided a clear, swift answer about a specific vaccine strategy. It’s not the answer we hoped for, but the search doesn’t end here,” Mitchell Warren, executive director of the nonprofit group AVAC: Global Advocacy for HIV Prevention, said in a statement.
April 25, 2013 — Reuters
Men & women demand rectal microbicides
For more than 30 years, the belief was that “safer sex = condoms”. But what happens when science shows that pills and gels can also prevent HIV? How do we rethink decades of prevention programs that equated condoms with safer sex and left few other choices?
April 1, 2013 — ACHIEVE Vol. 5, No. 4
Gilead drugs to prevent HIV spurned by African women in study
About two thirds of women didn’t consistently use Gilead’s daily pill Truvada or Viread, which came in the form of a pill or vaginal gel, according to the study released yesterday at the Conference on Retroviruses and Opportunistic Infections in Atlanta.
March 5, 2013 — Bloomberg News
HIV/AIDS: Disappointment in HIV prevention trial
A three-year clinical trial involving over 5,000 women in East and Southern Africa has found that pre-exposure prophylaxis (PrEP) – whether a vaginal gel or an oral tablet – is not effective at preventing HIV infection in young, unmarried women.
March 5, 2013 — IRIN
African trial of HIV drugs fail
The failure was due not to the methods — two different pills and a vaginal gel — but to the fact that the women did not use them consistently.
March 4, 2013 — New York Times
Daily ARV dose ineffective among Africa’s HIV-negative women
The daily use of a vaginal gel or oral medication does not appear to prevent HIV infection in young, unmarried African women, according to the results of a large HIV prevention trial…
March 4, 2013 — Mail & Guardian (South Africa)
HIV trial yields disappointing results
“Perhaps the most important finding was that although women came back to the clinic every month and were dedicated to the trial, the majority of these women didn’t actually take the product in the end.”
March 4, 2013 — Voice of America
Ending AIDS, part 2
Bringing major new medical breakthroughs to people in need requires both a realistic agenda and a political will.
February 6, 2013 — South Florida Gay News
Therapeutic Vaccines: Escaping the ‘viral escape’
With a checkered past, marred by decades of missteps, dead ends, controversies and a repeated need to change the direction of research, the quest for a therapeutic HIV vaccine is charting a slow but dogged path.
February 5, 2013 — AIDSMeds
Ending AIDS: A look at the future of prevention
Suddenly, people have begun to talk seriously about ending the global HIV epidemic.Medical breakthroughs have changed the global HIV landscape. These new developments include the following: Microbicides, treatment as prevention, PrEP, voluntary male circumcision, and preventing mother-to-child transmission.
January 30, 2013 — South Florida Gay News
→ Continue through the archives. Find articles from 2012 and older.